CORETAG, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,500 USD | -80.77% |
|
-.--% | -.--% |
Financials (USD)
| Sales 2022 | - | Sales 2023 | - | Capitalization | 1.12B |
|---|---|---|---|---|---|
| Net income 2022 | - | Net income 2023 | - | EV / Sales 2022 | - |
| Net Debt 2022 | 14.36K | Net Debt 2023 | 46.42K | EV / Sales 2023 | - |
| P/E ratio 2022 |
-33,196
x | P/E ratio 2023 |
-37,275
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 2.22% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -80.77% |
3 years
5.00
65 000.25
5 years
5.0065 000.25
10 years
5.0065 000.25
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 75 | 19-09-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 75 | 19-09-11 |
Coretag, Inc. is focused on the development of cancer imaging and targeted radiotherapy, based on its Necrosis Targeting Platform Technology (NTPT). The Company developed NTPT as a result of the discovery of a group of cyanine dyes which have selective targeting properties for intracellular proteins. These proteins become available for binding only when the cell membrane loses its integrity, which occurs once a cell has become necrotic. The Company has developed a portfolio of products that address high unmet needs in oncology. The Company develops targeted radiotherapy with 177Lu (lutetium) and 121Pb (lead) for the treatment of rapidly growing tumors and metastasis. It also develops targeted diagnostics with 89Zr (zirconium) and 111In (indium) for detecting and quantifying necrotic tissue in the human body.
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 1.12B | |
| -5.77% | 14.68B | |
| -40.71% | 2.71B | |
| -12.92% | 2.44B | |
| -8.78% | 1.51B | |
| +40.66% | 518M | |
| +91.79% | 502M | |
| +11.68% | 239M | |
| +1.67% | 183M | |
| -.--% | 168M |
- Stock Market
- Equities
- JMKJ Stock
